Abstract
BackgroundHormone receptor (HR)-positive breast cancer is a disease for which no immune checkpoint inhibitors have shown promise as effective therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors synergistically increased the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have